Background: Due to rapid technical advances, steeply declining sequencing costs, and the ever-increasing number of targeted therapies, it can be expected that extensive tumor sequencing such as whole-exome and whole-genome sequencing will soon be applied in standard care. Clinicians will thus be confronted with increasingly complex genetic information and multiple test-platforms to choose from. General medical training, meanwhile, can hardly keep up with the pace of innovation. Consequently, there is a rapidly growing gap between clinical knowledge and genetic potential in cancer care. Multidisciplinary Molecular Tumor Boards (MTBs) have been suggested as a means to address this disparity, but shared experiences are scarce in literature and no quality requirements or guidelines have been published to date.
Introduction
Over the past decades, we have seen impressive improvements in cancer treatment outcomes through combined use of genetic tumor testing and genetically matched targeted therapies [1] . Prime examples of this approach include imatinib for KIT mutated GIST [2] , vemurafenib for BRAF V600 mutated melanoma [3] , trastuzumab for HER2 amplified breast and gastric cancer [4, 5] , crizotinib for ALK activated and gefitinib, erlotinib, and afatinib for epidermal growth factor receptor (EGFR) mutated lung cancers [6, 7] . Meanwhile, the number of targeted therapies is continuously expanding and genetic tumor profiling is becoming more accurate and affordable [8] : commercial single-gene sequencing tests can now be bought for as little as $99 [9] , and the price of whole-genome sequencing (up to 30-fold coverage) has dropped from many millions in 2001 to several thousand dollars in 2015 [10] .
With continuously expanding possibilities for genetics-guided therapy on the one hand, and progressive insight in the complexity of such therapy on the other, it has been suggested to bring the required expertise together in Molecular Tumor Boards (MTBs) to ensure optimal care in an increasingly complex biomarker landscape [11] [12] [13] [14] . In line with the longstanding practice of multidisciplinary organ-specific tumor boards, MTBs may serve as a venue for continued education in-, facilitate interpretation and implementation of-, and ensure adequate delivery of genetics guided cancer care [11, 13] . Still, MTBs are a relatively new phenomenon and shared experiences are scarce in literature. No quality requirements or guidelines have been published to date. Based on literature review, a survey among hospitals in The Netherlands and our own experience with the establishment of a nationally operating MTB, we hereby provide a critical appraisal of current practice and present the author's joint view on what is needed for successful MTB implementation.
MTBs: why do we need them and what is holding us back?
MTBs are critical to close the growing gap between clinical practice and technologic potential in cancer care
Currently, the number of somatic tumor mutations used for standard treatment decisions is still quite limited and can easily be assessed via platforms capturing only these mutations (i.e. fixed or targeted gene panels). Gene panels do have their advantages such as high coverage, short turnaround time, relatively low costs and operational requirements, and no need for fresh frozen tissue or simultaneous germline testing. Such panels, however, can only assess variants with known clinical relevance and are not easily adapted when new biological or genetic insights emerge, since re-validation of the assay is required upon every change in test-content (e.g. addition of a new gene). Meanwhile, the demand for genetic testing will expand proportionally to the rapidly expanding genetic knowledge and related drug development. Large-scale sequencing platforms, such as whole-genome and whole-exome sequencing (WGS and WES, respectively), are already frequently used for research purposes, such as revealing prognostic or predictive profiles or screening patients for early clinical trials. It is expected that in the near-future, WES and WGS will be applied in standard care. Clinicians will thus be confronted with increasingly complex genetic information and more and more platforms to choose from: although large-scale sequencing is most informative in most cases, targeted in-depth sequencing may be preferred in others [e.g. to detect lowfrequency resistance clones, such as EGFR T790M and C797S mutations in non-small-cell lung cancer (NSCLC) [15] ].
The abundance of genetic tests and information provides a serious challenge, since most clinicians receive only limited training in genetics [13] : in a recent survey among physicians in a tertiary cancer center, 22% reported low confidence in their genetic knowledge and 18% anticipated testing their patients infrequently [16] . Limited knowledge may be one of the reasons for current genetic 'under-testing': several years after the approval of crizotinib and EGFR inhibitors, for example, around 50% of NSCLC patients in The Netherlands were tested for ALK rearrangements and approximately 70% for EGFR mutations. After ALK testing had been taken up in NSCLC guidelines, it took another 2 years to increase ALK-testing-coverage to 80% (S. M. Willems, personal communication). And although testing for HER2 status is now routinely carried out for breast cancer in the USA and Western Europe, this is not the case for gastric cancer [17] , nor for HER2 testing nor HER2-directed treatment in Eastern Europe [18] . Furthermore, most pathology and sequencing reports only report aberrations with direct and well-known treatment consequences for the tumor type in question. Genetic aberrations for which experimental agents and/or drug access programs are available may thus be overlooked. Given the interest of patients in alternative treatment opportunities, this is not an ideal situation.
Common definitions and quality requirements for MTBs are currently absent
MTBs are thus (increasingly) important, but what defines an MTB? To answer this question and to explore current practice, we carried out a literature review (supplementary Table S1 , available at Annals of Oncology online) and carried out a survey amongst Dutch hospitals (supplementary Table S2 , available at Annals of Oncology online). The survey was send out to all Center for Personalized Cancer Treatment-affiliated hospitals (n ¼ 39) [19] ; within this network (now including all major oncology centers in The Netherlands), WGS is offered to metastatic cancer patients before start of systemic treatment. A centralized MTB is available for interpretation and/or translation of the sequencing results into treatment recommendations. Hospitals with an MTB (other than the Center for Personalized Cancer Treatment MTB) were inquired about (i) the MTB's composition, workflow, and tools, (ii) impact of the MTB on clinical decision making, and (iii) encountered challenges and additional remarks. Out of 22 (56%) respondents, 9 (41%) reported having 1 MTB in place.
Based on the results of our review, survey, and interview, we found that at present the term MTB may refer to a wide variety of multidisciplinary group meetings: all are oriented to molecular tumor profiling and its relevance to treatment decisions, but attendance (for example) may range from 6 to 40 members per meeting [13, 20] , with 2-10 different specialties involved [13, 21] . Clinicians (mostly medical oncologists) and pathologists form the core of virtually every MTB and geneticists, medical biologists, and bioinformaticians take part in most MTBs, but other than that, composition varies widely. Altogether we did not find two MTBs with the exact same composition, not within literature, nor in our survey. In addition, different MTBs have different tasks, discuss different tests, and use different tools: while most MTBs deliberate on clinical implications of tumor profiling results, others may deliberate on whether a patient's tumor should be tested in the first place, and, if so, on which platform [12] . Tumor profiling may include small panels of known genetic variants [21] , larger panels covering hundreds of genes [22] , or WGS or WES [20, [23] [24] [25] [26] [27] To translate genomic profiles into therapeutic recommendations, however, searches across several databases are generally required because individually none of these repositories seems to have sufficient utility [22] . All in all, MTBs are expected to become highly important, but standards, guidelines, or quality requirements are currently absent.
Facilitating broad MTB access is a critical step forward
According to literature and our survey, MTBs are generally able to provide therapeutic recommendations (either standard-ofcare or experimental) for the majority of patients [11, 21, 22, 28] . Some reports state that patients receiving targeted therapy following MTB recommendations had superior outcomes compared with patients not receiving such therapy, including longer overall survival (hazard ratio 0.56, P ¼ 0.002) [29] , longer progression-free survival (86 versus 49 days, P ¼ 0.005) [30] and a trend toward longer time-on-treatment (7.6 versus 4.2 months, P ¼ 0.07) [31] . Although these studies are biased toward the fittest patients and not controlled for outcomes without MTB involvement, these observations do suggest that MTBs can help to inform treatment decisions. Other reported advantages include increased referral for genetic counseling [28, 32] , recognition of significant germline mutations [25] , and continued education of attendees [28] . MTBs improve clinician's understanding of assay strengths, limitations, and results [31] , increase oncologists' confidence in and efficiency of utilizing molecular diagnostics [13, 28] , and serve as a forum to disseminate information on laboratory updates, analysis software, and challenges in genetic data interpretation and utilization [28] . One of the most common reported obstacles, meanwhile, is a limited drug access [11] [12] [13] . MTBs may help to improve access, not only by keeping track of relevant clinical trials but also by registering MTB recommendation outcomes (i.e. did patients have access to the recommended therapy, did they benefit?) [14] .
Altogether, having access to MTBs likely improves and increases the application of genetics-guided cancer care. In our survey, however, overall <50% of hospitals and only 5% of nonacademic hospitals had access to an MTB. Multiple hospitals stated that they would like to participate in an MTB, but that logistic hurdles (such as inconvenient meeting hours, limited manpower and volume locally, and travel distance to in-person meetings) were currently refraining them from doing so. Facilitating broad MTB access, for academic and nonacademic hospitals, will thus be a challenging but critical step forward.
What is needed for optimal MTB functioning?
Given their importance and the current absence of guidelines and quality criteria, we hereby propose three basic necessities for successful MTB implementation: (i) global harmonization in cancer sequencing practices and procedures, (ii) minimal member and operational requirements, and (iii) an appropriate unsolicited findings policy. Our recommendations are summarized in Table 1 .
Global harmonization in cancer sequencing practices and procedures
Commonly reported challenges to MTB implementation include lack of standard tumor profiling tests [13, 22] , lack of standard criteria to define actionability [14, 32] , and identification of potentially pathogenic but unverified mutations (so-called variants of unknown significance [22] ). These findings are underscored by two recent articles by the Global Alliance for Genomics and Health, both emphasizing the presently siloed nature of genomic data sets and stressing the need for a globally harmonized, more effective data sharing culture: Vis et al. [27] carried out a survey on global practices for sequencing cancer samples and found wide variation in procedures, with bioinformatics pipelines employing different mutation calling/variant annotation algorithms. Siu et al. [33] reviewed key molecular profiling and big data initiatives in cancer care, including current datasharing challenges and potential solutions. When implemented, these initiatives would greatly facilitate interpretation of cancer genomics and (thus) optimal MTB functioning.
Minimal member and operational requirements
Appropriate implementation and interpretation of complex, large-scale sequencing data such as WGS and WES require expertise from clinical, pathological, biological, genetic, and technical perspective. We therefore propose the following minimal member requirements for any MTB that discusses large-scale sequencing results: (i) clinicians, representing all relevant specialisms, such as oncologists, pulmonologists, hematologists, (ii) (molecular) pathologists, (iii) clinical (molecular) biologists, (iv) geneticists, especially when germline testing (critical to WES and WGS interpretation) is included, and (v) bioinformaticians, especially when a bioinformatic gold-standard is currently absent (such as mutational load calculations). In our point of view, an MTB that does not include these five fields of expertise cannot guarantee adequate interpretation of WES and WGS data. However, MTB tiers or sub-commissions may be considered [14] , depending on the MTB aim and focus: geneticists and bioinformaticians may not be required for interpretation of variants identified by standardized tests (tier I), whereas interpretation of germline variants, variants of unknown significance and discussion of highly experimental treatment options (tier II) does require their expertise. Such organization may increase the MTB's efficiency and hence its clinical appreciation. We also recommend proven experience, including additional training (i.e. not included in the regular curriculum) in genetics and sequencing techniques for involved clinicians, and in oncology for involved pathologists, biologists, and geneticists. Such training may very well be organized within or parallel to the MTB. Some medical (preferably oncology) background is a pre for bioinformaticians too. In line with multidisciplinary organ-specific tumor boards [34] , the presence of the treating physician (or a delegated person) is advisable to ensure patient-centered decision making.
In addition, increasingly sophisticated knowledge libraries and bioinformatic technologies will be needed [13] . MTBs should thus have access to and experience with available cancer genome databases and specify which knowledge bases and annotation tools were used to come to treatment advice. Other operational requirements such as videoconferencing facilities (if necessary) and reporting and feedback systems may easily be overlooked but are equally important when organizing an MTB. Whereas organspecific, clinically oriented multidisciplinary tumor boards can generally use (electronic) health records for recording and reporting of their recommendations, MTBs may not have health record access (e.g. because access is denied to nonclinicians or because MTBs are shared between multiple hospitals). It is therefore recommended that MTBs organize a dedicated reporting system that can be uploaded in the patients' health record. Similarly, consideration should be given to which casuistry will (not) be discussed: which sample quality measures must be met (minimal tumor cell percentage, DNA yield?), which aberrations are self-evident (BRAF V600 mutations in melanoma?) and which aberrations are not (other BRAF mutations, and BRAF mutations in other tumor types?). Also, whether or not MTB recommendations were followed is generally not recorded nor are outcomes of MTB recommendations. Systematically registering these outcomes will give feedback on the quality of recommendations and may help to identify signs of activity in certain patients, while quantifying the lack of drug access for others. Categorized and clinician-assessed outcomes [e.g. '(i) advice not implemented due to limited drug access, (ii) advice implemented but not considered beneficial, (iii) advice implemented and clinical benefit observed', etc.] may be considered, especially when formal outcome assessments are confidential (i.e. in the context of clinical trials).
Unsolicited findings policy
Large-scale tumor DNA sequencing generally requires germline DNA sequencing as a reference to properly identify somatic mutations. Germline mutations may thus be encountered that are associated with increased susceptibility to hereditary diseases. Such findings, commonly referred to as unsolicited findings, may have immediate impact not only on the individual patient but also on his or her relatives. Although unsolicited findings are relatively rare (generally <1%, depending on the definition and genetic test used) [35, 36] , the overall incidence is expected to be substantial when large-scale sequencing is incorporated into routine clinical practice [37, 38] . In the absence of a widely accepted standard on how to handle and return unsolicited findings, it is advised that MTBs pre-define how sequencing results will be handled (i.e. which unsolicited findings will be reported, who discloses the information to patients and relatives, and do patients receive all information by default or is there a structured informed consent that allows them to choose what type of information they wish to receive?) [39, 40] .
Discussion

Conclusion
The quality of molecularly targeted treatment depends largely on the insights and knowledge of specifically trained individuals. Since the opportunities for (and, consequently, complexity of) genetic tumor testing and genetically guided treatment are In the absence of clear legislation on how to handle and return unsolicited findings, it is advised that MTBs pre-define how sequencing results will be handled if germ line testing is included (i.e. which unsolicited findings could be reported, who discloses the information to patients and relatives, and are patients informed by default or can they opt-in or opt-out?).
continuously expanding, patients rightfully expect that treatment opportunities are recognized and discussed [14] . MTBs can help to translate increasingly complex genetic information into patientcentered clinical decisions, thereby shepherding precision oncology into daily practice. The installation and organization of an MTB is critical to this extent, but standards, guidelines, or quality requirements are currently absent. This article evaluates current knowledge and needs and provides recommendations that may serve as a roadmap for successful MTB implementation.
